» Osteoporosis: Sandoz Announces Positive Results for Phase I/III Trials of Its Biosimilar Denosumab MyPharma Editions

Osteoporosis Sandoz Announces Positive Results for Phase IIII Trials

Posted on Friday, September 30, 2022 Sandoz, a global leader in generic and biosimilar medicines, has just announced new advances in its biosimilar medicines in development, with the publication of positive results from the ROSALIA integrated Phase I/III clinical trial for its treatment denosumab . “Biosimilars can have a significant positive impact on patient access … Read more

» Guerbet obtains one million euros from the BPI for its AI project in the early detection of pancreatic cancer MyPharma Editions

Guerbet obtains one million euros from the BPI for

Posted on Tuesday, September 27, 2022 Guerbet obtains funding of one million euros from the State via France 2030 following its participation in a call for projects concerning the acceleration strategy in digital health. The presentation of the work of Guerbet’s Artificial Intelligence (AI) research team, which could potentially offer a promising response to a … Read more

» Innate Pharma: Data from TELLOMAK Phase 2 Trial Demonstrate Clinical Activity of Lacutamab in Advanced Mycosis Fungoides MyPharma Editions

Innate Pharma Data from TELLOMAK Phase 2 Trial Demonstrate

Posted on Friday, September 23, 2022 Innate Pharma announced that its anti-KIR3DL2 antibody, lacutamab, has established clinical responses in patients with mycosis fungoides in the Phase 2 TELLOMAK trial. The results will be presented by Pr Martine Bagot, Head of the Dermatology Department at Saint-Louis Hospital (Paris), during an oral presentation at the EORTC CLTG1 … Read more

» Advanced Biodesign announces that it has obtained funding for its CRISPALDHin project as part of the France Relance plan MyPharma Editions

Advanced Biodesign announces that it has obtained funding for

Posted on Friday, September 23, 2022 Advanced BioDesign, a French biotechnology company specializing in the development of a new therapy against cancers resistant to standard treatments, and the TAGC Theories and approaches to genomic complexity laboratory (U1090 Inserm/Aix-Marseille University) will receive funding of 208,000 euros through the Plan France Relance for their collaboration around the … Read more

» Servier accelerates its digital transformation with Google Cloud MyPharma Editions

Servier accelerates its digital transformation with Google Cloud MyPharma

Posted on Friday, September 23, 2022 Servier, an international pharmaceutical group, and Google Cloud announce a strategic collaboration that marks a new stage in the digital transformation initiated by Servier. This agreement, centered on the use of data and artificial intelligence (AI), aims in particular to increase the Group’s therapeutic innovation capacities for the benefit … Read more

» Pancreatic cancer: Oncodesign Precision Medicine and Servier will collaborate to discover new therapeutic targets MyPharma Editions

Pancreatic cancer Oncodesign Precision Medicine and Servier will collaborate

Posted on Friday, September 23, 2022 Servier, an international pharmaceutical group, and Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign specializing in precision medicine, announce a collaborative research agreement, called “STarT Pancreas”, for the identification and validation of new therapeutic targets aimed at the development of new treatments for pancreatic ductal adenocarcinoma (PDAC). For a … Read more

» Pherecydes Pharma: creation of an international Medical Advisory Council MyPharma Editions

Pherecydes Pharma creation of an international Medical Advisory Council

Posted on Friday, September 16, 2022 Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, has announced the formation of a Medical Advisory Board, made up of leading international scientific and clinical experts specializing in infectiology. “We are delighted and honored to be able to cooperate with … Read more

» Genetic diseases: more than 8 million euros raised for research during an exceptional charity sale MyPharma Editions

Genetic diseases more than 8 million euros raised for

Posted on Wednesday, September 14, 2022 An exceptional auction of contemporary art and unique experiences was held at the Imagine Institute (AP-HP, Inserm, Université Paris Cité), the world’s leading center for research, care and education on diseases genetics located at the Necker-Enfants Malades Hospital AP-HP. The fourth edition of this Heroes for Imagine gala, created … Read more

» The industrial integrator TIBH obtains the renewal of its label for five years within the framework of the call for projects of the ANR MyPharma Editions

The industrial integrator TIBH obtains the renewal of its

Posted on Tuesday, September 13, 2022 The industrial integrator TIBH (Toulouse Industrial Biotechnology for Health) has obtained the renewal of its label for five years as part of the call for projects from the ANR (National Research Agency) “Biotherapy-Bioproduction Integrators”. The funding comes from the National Strategy for the Acceleration of Biotherapies and Bioproduction of … Read more

» Valneva: new positive results for its inactivated and adjuvanted vaccine against COVID-19 MyPharma Editions

Valneva new positive results for its inactivated and adjuvanted

Posted on Tuesday August 30th, 2022 Valneva, a vaccine company, today announced new positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine, VLA2001. Additional data from the Company’s pivotal trial VLA2001-301, ‘Cov-Compare’, showed persistent immunogenicity and early positive results for use as a heterologous booster following primary vaccination with ChAdOx1-S (AstraZeneca). The company previously … Read more